These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11600229)

  • 21. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
    Tietze LF; Krewer B
    Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
    Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
    Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy.
    Skelly JV; Knox RJ; Jenkins TC
    Mini Rev Med Chem; 2001 Sep; 1(3):293-306. PubMed ID: 12369976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
    Greco O; Dachs GU
    J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of self-immolative linkers for tumour-activated prodrug therapy.
    Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S
    Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy.
    Jung M
    Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting enzymes for cancer therapy: old enzymes in new roles.
    Deonarain MP; Epenetos AA
    Br J Cancer; 1994 Nov; 70(5):786-94. PubMed ID: 7947082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
    Denny WA
    Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developments with targeted enzymes in cancer therapy.
    Bagshawe KD; Sharma SK; Burke PJ; Melton RG; Knox RJ
    Curr Opin Immunol; 1999 Oct; 11(5):579-83. PubMed ID: 10508703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour endoproteases: the cutting edge of cancer drug delivery?
    Atkinson JM; Siller CS; Gill JH
    Br J Pharmacol; 2008 Apr; 153(7):1344-52. PubMed ID: 18204490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).
    Varner JD
    Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
    Hunter FW; Wouters BG; Wilson WR
    Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics.
    Hirata N; Fujisawa Y; Tanabe K; Harada H; Hiraoka M; Nishimoto S
    Org Biomol Chem; 2009 Feb; 7(4):651-4. PubMed ID: 19194578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
    Bagshawe KD; Sharma SK; Springer CJ; Rogers GT
    Ann Oncol; 1994 Dec; 5(10):879-91. PubMed ID: 7696159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds.
    Lesniewska-Kowiel MA; Muszalska I
    Eur J Med Chem; 2017 Mar; 129():53-71. PubMed ID: 28219047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.